Skip to main content
Top
Published in: Breast Cancer Research 1/2000

01-03-2000 | Meeting abstract

Expression profiling of BRCA1 associated breast tumors

Authors: EMJJ Berns, IL van Staveren, L Verhoog, JA Foekens, JGM Klijn

Published in: Breast Cancer Research | Special Issue 1/2000

Login to get access

Excerpt

BRCA1-associated breast tumours frequently show unfavourable features, ie poor differentiation, high proliferation indices, aneuploidy, ER- and PgR negativity, and TP53 positivity. These data are based on single gene analysis. Expression arrays, however, allow for the simultaneous investigation of multiple genes. We have used Atlas Human Cancer cDNA Expression Arrays (Clontech), on which 588 cancer-related genes are spotted, for an exploratory analysis. Profiles of one cell line and six tumours from patients with an inherited BRCA1 gene mutation were weighed against those from 15 patients without a family history who had similar clinico-pathological characteristics which are collected in our computerised database system. Total RNA isolation was performed according to standard procedures. RNAs were used to synthesise 32P-radiolabeled cDNA for hybridisation to the cancer cDNA expression arrays, according to the manufacturer's instructions. Data were acquired and quantified using the Molecular Dynamics PhosphoImager and ImageQuant software (Molecular Dynamics, Sunnyvale, USA). The levels of the lowest and highest expressed genes differed at 100- or 1000-fold. In an exploratory analysis we have considered only the upper 30% ranking of the signals for each tumor sample as 'high' expression (H), and the data were dichotomised: high (H) vs low (L). …
Metadata
Title
Expression profiling of BRCA1 associated breast tumors
Authors
EMJJ Berns
IL van Staveren
L Verhoog
JA Foekens
JGM Klijn
Publication date
01-03-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr126

Other articles of this Special Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine